查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1571496

重组 DNA 技术市场规模、份额和趋势分析报告：按产品、组件、应用、最终用途和细分市场进行预测，2024-2030 年

Recombinant DNA Technology Market Size, Share & Trends Analysis Report By Product (Medical, Non-medical), By Component (Expression System), By Application, By End Use, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 100 Pages | 商品交期: 2-10个工作天内

价格
简介目录

重组 DNA 技术市场成长与趋势：

Grand View Research, Inc.最新报告显示，预计2024年至2030年全球重组DNA技术市场规模将以5.4%的复合年增长率成长，2030年将达到10,671亿美元。

重组人类胰岛素在治疗糖尿病方面的成功引发了许多其他重组疗法和药物的开发。这导致了重组DNA（rDNA）技术的巨大成功。这项技术为阐明该疾病与其有效治疗之间的差距提供了重要视角。

该技术在动物产品开发、基因改造作物开发、生物农药和生质燃料生产以及基因治疗中的广泛和成功应用预计将在预测期内推动该技术的采用。

基因改造 (GM) 产品的使用，例如使用 rDNA 方法开发的基因改造动物，已被证明对于加速医学研究至关重要。此外，还进行了 3,000 多项科学研究来评估基因改造产品的安全性及其对人类健康和环境的影响。

此外，对疾病治疗的有效治疗剂的需求不断增加，使得重组蛋白生产能力的需求增加了数倍。上述事实表明，该领域的技术进步正在推动成长。

据包括孟山都公司在内的基因改造作物支持者称，基改作物是近年来应用最迅速、最广泛的农业创新之一。预计这将促进 rDNA 技术在非传统应用中的采用。

重组 DNA 技术市场报告亮点

  • 2023年，医用rDNA产品将在销售份额中占据主导地位。
  • 这是因为胰岛素的商业性成功鼓励公司进一步开发重组药物。
  • 哺乳动物表现系统因其高效的瞬时和稳定的表达能力而获得了最大的市场份额。
  • 使用哺乳动物表现系统改进的高产量培养基也支持了这一份额。
  • 健康和疾病领域占销售额的最大份额。
  • 基因治疗、抗体生产、药物代谢研究、重组治疗和疫苗开发被认为是该技术在人类医疗保健管理中的主要应用。
  • 重组DNA技术市场包括各种最终用途部门，例如製药和生物技术公司、学术和研究机构以及其他工业实体。
  • 从最终用途来看，由于大量生物製药公司采用 rDNA 产品，製药和生物技术公司估计是最大的细分市场。
  • 由于存在有关核准基因改造疗法和产品的有效法规，北美占据了最大份额。
  • 亚太地区预计将成为成长最快的区域市场。
  • 与西方国家相比，在印度等亚洲国家进行临床试验的成本相对较低。因此，世界上许多生物製药开发公司正在向该地区扩张。
  • 百健 (Biogen)、安进 (Amgen)、礼来 (Eli Lilly)、孟山都 (Monsanto)、诺华 (Novartis) 和罗氏 (F. Hoffmann-La Roche) 是在该地区运营的主要企业。

目录

第一章调查方法和范围

第 2 章执行摘要

第 3 章重组 DNA 技术市场变数、趋势与范围

  • 市场介绍/系统展望
  • 市场规模及成长前景
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
  • 重组DNA技术市场分析工具
    • 波特的分析
    • PESTEL分析

第四章 重组DNA技术市场：产品评估与趋势分析

  • 细分仪表板
  • 重组 DNA 技术市场：2023 年与 2030 年产品变异分析
  • 医疗保健
  • 非医疗的

第五章重组DNA技术市场：成分估计与趋势分析

  • 细分仪表板
  • 重组 DNA 技术市场：成分变异分析，2023 年和 2030 年
  • 表达系统
  • 克隆载体

第六章 重组DNA技术市场：应用预估及趋势分析

  • 细分仪表板
  • 重组 DNA 技术市场：2023 年与 2030 年应用变异分析
  • 食品和农业
  • 健康与疾病
    • 人类
    • 动物
  • 其他用途

第 7 章 重组 DNA 技术市场：最终用途估计与趋势分析

  • 细分仪表板
  • 重组 DNA 技术市场：最终用途变异分析，2023 年和 2030 年
  • 生物技术和製药公司
  • 学术和政府研究机构
  • 其他用途

第八章重组DNA技术市场：区域估计与趋势分析

  • 2023 年及 2030 年重组 DNA 技术市场占有率（按地区）
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 丹麦
    • 瑞典
    • 挪威
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 韩国
    • 澳洲
    • 泰国
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中东和非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第9章 竞争格局

  • 主要市场参与企业的最新趋势和影响分析
  • 公司分类
  • 企业热力图分析
  • 公司简介
    • Pfizer Inc.
    • Sanofi
    • New England Biolabs
    • GlaxoSmithKline plc
    • GenScript
    • Thermo Fisher Scientific Inc.
    • Biogen Inc.
    • Merck &Co., Inc.
    • Amgen Inc.
    • Monsanto Company
    • F. Hoffmann-La Roche Ltd
    • Novartis AG
    • Eli Lilly and Company
简介目录
Product Code: GVR-1-68038-872-5

Recombinant DNA Technology Market Growth & Trends:

The global recombinant DNA technology market size is expected to reach USD 1,067.1 billion by 2030, expanding at a CAGR of 5.4% from 2024 to 2030, according to a new report by Grand View Research, Inc. The success of genetically engineered human insulin in diabetes treatment has triggered the development of many other recombinant therapeutics and drugs. This has translated to the huge success of Recombinant DNA (rDNA) technology. This technology has offered significant prospects for elucidating the gap between disease and its effective treatment.

Widespread successful application of this technique in veterinary product development, genetically modified crop development, biopesticides & biofuel production, and gene therapy, are expected to spur the adoption of this technology throughout the forecast period.

The use of Genetically Modified (GM) products, such as GM animals, developed using the rDNA method are found to be indispensable to accelerate medical research. Furthermore, more than 3000 scientific studies have been carried out to assess GM product safety in context to its impact on human health and the environment.

In addition, there is a rising need to improve the recombinant proteins' production capacity by several folds, owing to an increase in demand for effective therapeutics for disease treatment. The aforementioned fact pronounces the technological advances in this sector thus driving growth.

As per Monsanto and other proponents of GM crops, genetic engineering is one of the fastest and widely adopted agricultural innovations over the past few years. This, in turn, is expected to bolster the adoption of rDNA technology for non-traditional applications.

Recombinant DNA Technology Market Report Highlights:

  • Medical rDNA products dominated the share in 2023 in terms of revenue generation.
  • This can be attributed to the commercial success of insulin which has prompted firms for further development of recombinant drugs.
  • Owing to efficient transient and stable expression capabilities, mammalian expression system captured the largest share.
  • This share is also supported by the improvements in media for high yield using a mammalian expression system.
  • Health & disease accounted with the largest share in terms of revenue.
  • Gene therapy, antibodies production, drug metabolism investigation, recombinant therapeutic & vaccine development are recognized as major applications of this technology in human healthcare management.
  • Various end-use segments served by this recombinant DNA technology market encompass pharmaceutical & biotech entities, academic & research institutes, and other industrial entities.
  • End-use wise, pharmaceutical and biotechnology firms are estimated to be the largest segment owing to the presence of a substantial number of biopharma entities that have adopted rDNA products.
  • North America held the largest share owing to the presence of effective regulations pertaining to the approval of recombinant therapeutics as well as GM products.
  • Asia Pacific is expected to emerge as the fastest growing regional market.
  • Conducting clinical trials in Asian countries such as India is relatively less expensive compared to western countries. This has resulted in the migration of several global biopharmaceutical developers towards this region.
  • Biogen; Amgen Inc., Eli Lilly and Company, Monsanto Company, Novartis AG, and F. Hoffmann-La Roche Ltd are some of the major companies operating in this space.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Market Definitions
  • 1.3. Research Methodology
    • 1.3.1. Information Procurement
    • 1.3.2. Information or Data Analysis
    • 1.3.3. Market Formulation & Data Visualization
    • 1.3.4. Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1. List of Data Sources

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. Recombinant DNA Technology Market Variables, Trends, & Scope

  • 3.1. Market Introduction/Lineage Outlook
  • 3.2. Market Size and Growth Prospects (USD Billion)
  • 3.3. Market Dynamics
    • 3.3.1. Market Drivers Analysis
    • 3.3.2. Market Restraints Analysis
  • 3.4. Recombinant DNA Technology Market Analysis Tools
    • 3.4.1. Porter's Analysis
      • 3.4.1.1. Bargaining power of the suppliers
      • 3.4.1.2. Bargaining power of the buyers
      • 3.4.1.3. Threats of substitution
      • 3.4.1.4. Threats from new entrants
      • 3.4.1.5. Competitive rivalry
    • 3.4.2. PESTEL Analysis
      • 3.4.2.1. Political landscape
      • 3.4.2.2. Economic and Social landscape
      • 3.4.2.3. Technological landscape
      • 3.4.2.4. Environmental landscape
      • 3.4.2.5. Legal landscape

Chapter 4. Recombinant DNA Technology Market: Product Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Recombinant DNA Technology Market: Product Movement Analysis, 2023 & 2030 (USD Billion)
  • 4.3. Medical
    • 4.3.1. Medical Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 4.3.2. Therapeutic Agent
      • 4.3.2.1. Therapeutic Agent Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 4.3.3. Human Protein
      • 4.3.3.1. Human Protein Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 4.3.4. Vaccine
      • 4.3.4.1. Vaccine Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 4.4. Non-medical
    • 4.4.1. Non-medical Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 4.4.2. Biotech Crops
      • 4.4.2.1. Biotech Crops Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 4.4.3. Specialty Chemicals
      • 4.4.3.1. Specialty Chemicals Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 4.4.4. Other Non-medical Products
      • 4.4.4.1. Other Non-medical Products Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)

Chapter 5. Recombinant DNA Technology Market: Component Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Recombinant DNA Technology Market: Component Movement Analysis, 2023 & 2030 (USD Billion)
  • 5.3. Expression System
    • 5.3.1. Expression System Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 5.3.2. Mammalian
      • 5.3.2.1. Mammalian Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 5.3.3. Bacteria
      • 5.3.3.1. Bacteria Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 5.3.4. Yeast
      • 5.3.4.1. Yeast Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 5.3.5. Baculovirus / Insect
      • 5.3.5.1. Baculovirus / Insect Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 5.3.6. Other Expression Systems
      • 5.3.6.1. Other Expression Systems Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 5.4. Cloning Vector
    • 5.4.1. Cloning Vector Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)

Chapter 6. Recombinant DNA Technology Market: Application Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. Recombinant DNA Technology Market: Application Movement Analysis, 2023 & 2030 (USD Billion)
  • 6.3. Food & Agriculture
    • 6.3.1. Food & Agriculture Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 6.4. Health & Disease
    • 6.4.1. Health & Disease Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 6.4.2. Human
      • 6.4.2.1. Human Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 6.4.3. Animal
      • 6.4.3.1. Animal Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 6.5. Other Applications
    • 6.5.1. Other Applications Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)

Chapter 7. Recombinant DNA Technology Market: End Use Estimates & Trend Analysis

  • 7.1. Segment Dashboard
  • 7.2. Recombinant DNA Technology Market: End Use Movement Analysis, 2023 & 2030 (USD Billion)
  • 7.3. Biotechnology and Pharmaceutical Companies
    • 7.3.1. Biotechnology and Pharmaceutical Companies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.4. Academic & Government Research Institutes
    • 7.4.1. Academic & Government Research Institutes Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.5. Other End Uses
    • 7.5.1. Other End Uses Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)

Chapter 8. Recombinant DNA Technology Market: Regional Estimates & Trend Analysis

  • 8.1. Recombinant DNA Technology Market Share, By Region, 2023 & 2030 (USD Billion)
  • 8.2. North America
    • 8.2.1. North America Recombinant DNA Technology Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 8.2.2. U.S.
      • 8.2.2.1. U.S. Recombinant DNA Technology Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 8.2.3. Canada
      • 8.2.3.1. Canada Recombinant DNA Technology Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 8.2.4. Mexico
      • 8.2.4.1. Mexico Recombinant DNA Technology Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 8.3. Europe
    • 8.3.1. Europe Recombinant DNA Technology Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 8.3.2. UK
      • 8.3.2.1. UK Recombinant DNA Technology Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 8.3.3. Germany
      • 8.3.3.1. Germany Recombinant DNA Technology Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 8.3.4. France
      • 8.3.4.1. France Recombinant DNA Technology Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 8.3.5. Italy
      • 8.3.5.1. Italy Recombinant DNA Technology Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 8.3.6. Spain
      • 8.3.6.1. Spain Recombinant DNA Technology Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 8.3.7. Denmark
      • 8.3.7.1. Denmark Recombinant DNA Technology Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 8.3.8. Sweden
      • 8.3.8.1. Sweden Recombinant DNA Technology Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 8.3.9. Norway
      • 8.3.9.1. Norway Recombinant DNA Technology Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 8.4. Asia Pacific
    • 8.4.1. Asia Pacific Recombinant DNA Technology Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 8.4.2. Japan
      • 8.4.2.1. Japan Recombinant DNA Technology Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 8.4.3. China
      • 8.4.3.1. China Recombinant DNA Technology Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 8.4.4. India
      • 8.4.4.1. India Recombinant DNA Technology Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 8.4.5. South Korea
      • 8.4.5.1. South Korea Recombinant DNA Technology Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 8.4.6. Australia
      • 8.4.6.1. Australia Recombinant DNA Technology Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 8.4.7. Thailand
      • 8.4.7.1. Thailand Recombinant DNA Technology Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 8.5. Latin America
    • 8.5.1. Latin America Recombinant DNA Technology Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 8.5.2. Brazil
      • 8.5.2.1. Brazil Recombinant DNA Technology Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 8.5.3. Argentina
      • 8.5.3.1. Argentina Recombinant DNA Technology Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 8.6. Middle East and Africa
    • 8.6.1. Middle East and Africa Recombinant DNA Technology Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 8.6.2. South Africa
      • 8.6.2.1. South Africa Recombinant DNA Technology Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 8.6.3. Saudi Arabia
      • 8.6.3.1. Saudi Arabia Recombinant DNA Technology Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 8.6.4. UAE
      • 8.6.4.1. UAE Recombinant DNA Technology Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 8.6.5. Kuwait
      • 8.6.5.1. Kuwait Recombinant DNA Technology Market Estimates and Forecasts, 2018 - 2030 (USD Billion)

Chapter 9. Competitive Landscape

  • 9.1. Recent Developments & Impact Analysis by Key Market Participants
  • 9.2. Company Categorization
  • 9.3. Company Heat Map Analysis
  • 9.4. Company Profiles
    • 9.4.1. Pfizer Inc.
      • 9.4.1.1. Participant's Overview
      • 9.4.1.2. Financial Performance
      • 9.4.1.3. Product Benchmarking
      • 9.4.1.4. Recent Developments/Strategic Initiatives
    • 9.4.2. Sanofi
      • 9.4.2.1. Participant's Overview
      • 9.4.2.2. Financial Performance
      • 9.4.2.3. Product Benchmarking
      • 9.4.2.4. Recent Developments/Strategic Initiatives
    • 9.4.3. New England Biolabs
      • 9.4.3.1. Participant's Overview
      • 9.4.3.2. Financial Performance
      • 9.4.3.3. Product Benchmarking
      • 9.4.3.4. Recent Developments/Strategic Initiatives
    • 9.4.4. GlaxoSmithKline plc
      • 9.4.4.1. Participant's Overview
      • 9.4.4.2. Financial Performance
      • 9.4.4.3. Product Benchmarking
      • 9.4.4.4. Recent Developments/Strategic Initiatives
    • 9.4.5. GenScript
      • 9.4.5.1. Participant's Overview
      • 9.4.5.2. Financial Performance
      • 9.4.5.3. Product Benchmarking
      • 9.4.5.4. Recent Developments/Strategic Initiatives
    • 9.4.6. Thermo Fisher Scientific Inc.
      • 9.4.6.1. Participant's Overview
      • 9.4.6.2. Financial Performance
      • 9.4.6.3. Product Benchmarking
      • 9.4.6.4. Recent Developments/Strategic Initiatives
    • 9.4.7. Biogen Inc.
      • 9.4.7.1. Participant's Overview
      • 9.4.7.2. Financial Performance
      • 9.4.7.3. Product Benchmarking
      • 9.4.7.4. Recent Developments/Strategic Initiatives
    • 9.4.8. Merck & Co., Inc.
      • 9.4.8.1. Participant's Overview
      • 9.4.8.2. Financial Performance
      • 9.4.8.3. Product Benchmarking
      • 9.4.8.4. Recent Developments/Strategic Initiatives
    • 9.4.9. Amgen Inc.
      • 9.4.9.1. Participant's Overview
      • 9.4.9.2. Financial Performance
      • 9.4.9.3. Product Benchmarking
      • 9.4.9.4. Recent Developments/Strategic Initiatives
    • 9.4.10. Monsanto Company
      • 9.4.10.1. Participant's Overview
      • 9.4.10.2. Financial Performance
      • 9.4.10.3. Product Benchmarking
      • 9.4.10.4. Recent Developments/Strategic Initiatives
    • 9.4.11. F. Hoffmann-La Roche Ltd
      • 9.4.11.1. Participant's Overview
      • 9.4.11.2. Financial Performance
      • 9.4.11.3. Product Benchmarking
      • 9.4.11.4. Recent Developments/Strategic Initiatives
    • 9.4.12. Novartis AG
      • 9.4.12.1. Participant's Overview
      • 9.4.12.2. Financial Performance
      • 9.4.12.3. Product Benchmarking
      • 9.4.12.4. Recent Developments/Strategic Initiatives
    • 9.4.13. Eli Lilly and Company
      • 9.4.13.1. Participant's Overview
      • 9.4.13.2. Financial Performance
      • 9.4.13.3. Product Benchmarking
      • 9.4.13.4. Recent Developments/Strategic Initiatives